NEW YORK (GenomeWeb) – Chembio Diagnostics today priced its public offering of about 1.8 million shares of its common stock at $6.75 per share.

The company estimated net proceeds from the offering, which is expected to close on or about Feb. 13, to be $11.2 million.

Proceeds will be used for business expansion and working capital, including product development, operational expansion or improvements — such as new automated equipment and a facilities update, clinical trials, and other related activities — and sales and marketing, Chembio said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.


In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.